title: Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases.
abstract: Development of liver disease after hematopoietic cell transplantation is common and the causes diverse. Infection by hepatitis C virus (HCV) can be seen in patients who are chronically infected before transplant or from passage of virus from an infected donor; the normal 10-year course of hepatitis C after transplant is one of waxing and waning of serum aminotransferase enzymes, with little morbidity. In the series of 3 patients reported here, the course of hepatitis C was rapidly fatal, with the onset of jaundice at day 60 to 80 after transplant and liver histology typical of fibrosing cholestatic hepatitis (marked bile ductular proliferation, ballooned hepatocytes, and associated collagenous fibrosis centered around ductules). The bile ductular reaction pattern varied from elongated structures without a recognizable lumen to a pattern of cuboidal cells with a clear lumen. There was significant cholestasis with bile within hepatocytes and canalicular bile plugs. In situ HCV RNA hybridization studies from 1 patient showed a robust infection with high levels of HCV-infected hepatocytes and active viral replication. All 3 patients were on immunosuppressive drugs after transplant, including mycophenolate mofetil (MMF), which irreversibly inhibits inosine monophosphate dehydrogenase, on which T and B lymphocytes are dependent. We speculate that fatal fibrosing cholestatic hepatitis C in these cases was related to the immunosuppressive effects of MMF, as we had not recognized this presentation of HCV infection before the introduction of MMF.
authors.affiliation: Departments of *Medicine †Pathology §Laboratory Medicine, University of Washington School of Medicine ‡Clinical Research Division, Fred Hutchinson Cancer Research Center ∥VA Puget Sound Health Care System, Seattle, WA.
authors.forename: Ashley T
authors.initials: AT
authors.lastname: Evans
authors.forename: Keith R
authors.initials: KR
authors.lastname: Loeb
authors.forename: Howard M
authors.initials: HM
authors.lastname: Shulman
authors.forename: Sajida
authors.initials: S
authors.lastname: Hassan
authors.forename: Wan Chong
authors.initials: WC
authors.lastname: Qiu
authors.forename: David M
authors.initials: DM
authors.lastname: Hockenbery
authors.forename: George N
authors.initials: GN
authors.lastname: Ioannou
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Chauncey
authors.forename: David R
authors.initials: DR
authors.lastname: Gretch
authors.forename: George B
authors.initials: GB
authors.lastname: McDonald
mesh_terms: D000328:Adult; D002779:Cholestasis / Q000209:etiology / Q000276:immunology; D017809:Fatal Outcome; D005355:Fibrosis / Q000209:etiology / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006526:Hepatitis C / Q000209:etiology* / Q000276:immunology / Q000473:pathology*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007938:Leukemia / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid